Ublituximab-xiiy (Briumvi)

METRO INFUSION CENTER

REFERRAL STATUS: ☐ New Referral ☐ Dose or Frequency Change ☐ Order Renewal

Infusion Office Preference: ____

PATIENT INFORMATION		
Date:	Patient Name:	DOB:
☐ NKDA Allergies:	Weight (lbs / kg):	Height:
Patient Status: ☐ New to Therapy ☐ Continuing Therapy - Last Treatment Date:		Next Due Date:

PROVIDER INFORMATION			
Office Contact Name:	Office Email:		
Prescribing Providers Name:	Provider NPI:		
Office Address:	City:	State:	Zip:
Office Phone Number:	Office Fax Number:		

DIAGNOSIS AND ICD 10 CODE	
☐Relapsing-Remitting Multiple Sclerosis	ICD-10 Code: G35
☐Secondary Progressive Multiple Sclerosis	ICD-10 Code: G35
☐Primary Progressive Multiple Sclerosis	ICD-10 Code: G35

REQUIRED DOCUMENTATION/Testing	
☐ This signed order form by the provider ☐ Patient demographics AND insurance info ☐ Clinical/Progress notes supporting primary dx	☐ Labs and Tests supporting primary diagnosis ☐ Hepatitis B Test Results: HBsAg & Total HepB Core Antibody
Current MS treatment and end of current therapy date:	

PRE-MEDICATION ORDERS	
☐ acetaminophen (Tylenol) PO ☐ 500mg ☐ 650mg ☐ 1000mg ☐ diphenhydramine (Benadryl) PO / IV ☐ 25mg ☐ 50mg (if route is not circled PO will be administered)) ☐ methylprednisolone (Solu-Medrol) IV ☐ 60mg ☐ 100 mg ☐ _____ mg ☐ other:	*Note: manufacturer recommended premedication regimen is Tylenol, Solu-Medrol and Benadryl*

MEDICATION ORDERS	
Initial Dosing	☐ Briumvi 150 mg IV x 1 dose then 450 mg IV at week 2
Maintenance Dosing	☐ Briumvi 450 mg IV every 24 weeks (to begin 24 weeks from first infusion)
Other Dosing :	☐ Briumvi ________mg IV _______________________
Refills*: ☐ None ☐ X6 months ☐ X1 year ☐ Other: _____________ **(if not indicated order will expire one year from date signed)*	

SPECIAL INSTRUCTIONS
☐ Urine pregnancy test prior to each infusion

Provider Name (Print) **Physician Signature:** **Date:**

Fax referral to 866-507-1164 or email to MICreferral@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become part of the patient's medical record.

Revised 1/27/23